Reference entry · Endogenous 28-amino-acid neuropeptide
VIP
Also known as: Vasoactive intestinal peptide · PHM-27 related neuropeptide
- Class
- Endogenous 28-amino-acid neuropeptide
- Size
- 28 amino acids
- Primary targets (literature)
- VIP receptors (VPAC1, VPAC2); PACAP receptor family literature
- Regulatory context
- Not FDA-approved as a catalog injectable drug. Endogenous peptide studied across disciplines; RUO supply requires batch-specific analytics.
Overview
VIP is a widely distributed neuropeptide with extensive formal research in immunology, circadian biology, and neuroprotection. It is analytically well characterized but sensitive to oxidation and proteolysis — material handling matters as much as sequence identity.
Mechanism in research literature
VIP receptor activation stimulates adenylyl cyclase and cAMP signaling in immune cells, neurons, and endocrine tissues — producing context-dependent anti-inflammatory, chronobiological, and neurotrophic observations in research models.
Common research focus areas
- T-cell and macrophage immunomodulation assays
- Circadian clock gene expression models
- VPAC1/VPAC2 receptor pharmacology
- Oxidation-sensitive peptide storage and COA verification
Full literature roundup
Read the cited research summary
A 28-residue neuropeptide studied across immunology, circadian biology, and neuroprotection. Receptor pharmacology, literature breadth, and RUO material standards.
VIP research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.